Why The SOPHiA GENETICS (SOPH) Narrative Is Shifting On Richer Valuation And Growth Expectations

Simply Wall St

Thu, February 26, 2026 at 5:17 PM GMT+9 4 min read

In this article:

SOPH

+1.32%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Analysts have lifted their price target for SOPHiA GENETICS by $1, signalling a slightly higher view of what the shares could reasonably be worth. That move is grounded in updated models, where more optimistic voices see enough support to justify the extra $1, while cautious analysts question how much cushion it really provides. As you read on, you will see how this evolving narrative might shape the way you track the stock from here.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value SOPHiA GENETICS.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Guggenheim has lifted its price target for SOPHiA GENETICS by $1, which signals incrementally higher conviction about where the shares could reasonably trade based on its updated research.

The target change from Guggenheim suggests its analysts see enough support in their models to justify a slightly higher valuation. Some investors may read this as a constructive signal on the company’s execution and growth prospects.

🐻 Bearish Takeaways

Even with the $1 price target increase, more cautious readers of the Guggenheim work may question how much downside protection exists if the business does not track in line with its assumptions.

The modest size of the revision from Guggenheim also leaves room for debate on whether the risk and reward profile has meaningfully shifted, particularly for investors who prefer a larger valuation cushion.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

NasdaqGS:SOPH 1-Year Stock Price Chart

We’ve flagged 1 risk for SOPHiA GENETICS. See which could impact your investment.

What’s in the News

SOPHiA GENETICS added two of the largest U.S. healthcare systems to its network, with plans to use the SOPHiA DDM platform for genomic testing on up to 60,000 patients annually for hereditary cancers and rare diseases across the West Coast and Midwest.

The new U.S. health system partners intend to use SOPHiA DDM for Enhanced Exome analysis covering more than 20,000 genes, aiming for faster test turnaround, streamlined costs, and expanded internal research tied to AI driven precision medicine.

The company announced a collaboration with The University of Texas MD Anderson Cancer Center to co develop next generation sequencing oncology tests and bioinformatics pipelines that process complex genomic and RNA sequencing data for cancer care insights.

SOPHiA GENETICS and MD Anderson outlined a series of research programs on tumor evolution, reliability of genomic testing, and matching patients to clinical trials or research options. The company also issued 2026 guidance for full year revenue of US$92m to US$94m with year over year growth of about 20% to 22%.

 






Story Continues  

How This Changes the Fair Value For SOPHiA GENETICS

Fair Value is held at US$7.67 in the latest update, unchanged from the prior US$7.67 modelled level.

Revenue Growth assumption remains about 19.92% in both the prior and updated models.

Net Profit Margin stays roughly 6.93% in both the earlier and updated assumptions.

Future P/E moves from 78.16x to 79.26x in the latest set of assumptions.

Discount Rate is adjusted slightly from 8.44% to 8.43% in the updated model.

Never Miss an Update: Follow The Narrative

Narratives connect a company’s business story to a set of financial assumptions, so you can see how product, customer, and industry developments flow through to revenue, margins, and fair value. They update as new partnerships, guidance, and risks come through.

Head over to the Simply Wall St Community and follow the Narrative on SOPHiA GENETICS to stay up to date on:

How growing demand for precision medicine and cloud based healthcare analytics may relate to platform adoption, recurring revenue, and usage of the SOPHiA DDM platform.

The role of higher value multimodal applications, large health system customers, and partnerships such as AstraZeneca and MD Anderson in shaping the company’s earnings profile.

Key risks around ongoing losses, customer concentration, foreign exchange swings, intense genomics competition, and stricter global data and compliance rules.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include SOPH.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info